We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA (TOCIAION)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04239196
Recruitment Status : Recruiting
First Posted : January 23, 2020
Last Update Posted : March 18, 2022
Sponsor:
Collaborator:
Roche Chugai
Information provided by (Responsible Party):
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts

Brief Summary:
AION is the main cause of blindness in patients with GCA. High dose steroid is the reference treatment of this condition, but medical unmet need remains. Subcutaneous tocilizumab, a targeted biotherapy, recently received marketing authorization for the treatment of GCA, but only demonstrated at yet that it can allow steroid dose sparing. The aim of this study is to assess the benefit of tocilizumab and IV steroids combination or IV steroids alone, in the treatment of AION due to GCA.

Condition or disease Intervention/treatment Phase
Giant Cell Arteritis Optic Ischaemic Neuropathy Drug: tocilizumab and IV steroids combination Other: IV steroids combination alone Phase 2

Detailed Description:
Tocilizumab will be proposed to eligible patients as an emergency treatment, in addition to the standard high-dose steroid treatment. Each patient will receive the reference treatment, i.e. one pulse of high dose intravenous methylprednisolone per day during 3 days, followed by 1 mg/kg/day oral prednisone, and low dose aspirin. Depending on the randomization, each patient will receive the reference treatment only, or will received in addition to the reference treatment four subcutaneous injections of tocilizumab 162 mg over one month (1 injection per week), the first tocilizumab injection being delivered on the same day than the first steroid IV pulse. Study visits will take place at 4, 8 and 13 weeks. The primary endpoint will be the ocular improvement at W8, defined as an increase of at least two lines of visual acuity on the ETRS chart. For each patient, the duration of participation will by of 3 months. The study duration is expected to be 15 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 58 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: optimal Simon two-stage design
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Label Phase II Randomized Non-comparative Study of SC Tocilizumab Associated With IV Pulse Steroid Versus IV Pulse Steroid Alone for the Treatment of Acute Anterior Ischemic Optic Neuropathy Associated With Giant Cell Arteritis
Actual Study Start Date : September 10, 2020
Actual Primary Completion Date : November 9, 2020
Estimated Study Completion Date : December 10, 2022


Arm Intervention/treatment
Experimental: tocilizumab and IV steroids combination
Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months. Patients will receive in addition to the reference treatment four subcutaneous injections of tocilizumab 162 mg over one month (1 injection per week).
Drug: tocilizumab and IV steroids combination

Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months.

Patients will receive in addition to the reference treatment four subcutaneous injections of tocilizumab 162 mg over one month (1 injection per week).


IV steroids combination alone
Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months.
Other: IV steroids combination alone
Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months.




Primary Outcome Measures :
  1. ocular change [ Time Frame: Week 8 ]
    The primary endpoint will be the ocular change at Week 8. This change will be defined as the increase of at least two lines of visual acuity on the ETDRS chart.


Secondary Outcome Measures :
  1. Decrease of vision [ Time Frame: Week 8 ]

    Stabilization of vision, as judged at Week 8 after treatment start, correspond to a lack of deterioration :

    • If the patient can see the light initially, no light perception at W8 will represent a deterioration
    • If the patient is able to count finger at any distance, but the visual acuity is less than 20/400 on the ETRS chart, a "off chart" visual acuity at W8 will represent a deterioration
    • If initial visual acuity is equal or more than 20/400, a loss of 2 lines or more on the ETDRS at Week 8 will represent deterioration

  2. Occurrence of a visual improvement [ Time Frame: Week 4 and Week 13 ]
    Occurrence of a visual improvement defined as an increase of two lines or more of visual acuity on ETDRS chart, a clinically significant difference, at Week 4 and Week 13

  3. Change in Mean Deviation [ Time Frame: weeks 4, 8, and 13 ]
    Change in Mean Deviation (MD) measured on an automatized Visual Field (SITA Standard Humphrey 24-2) at weeks 4, 8, and 13

  4. Changes in angio-OCT [ Time Frame: Week 0 and Week 4 ]
    Changes in angio-OCT between baseline and Week 4 : superficial and deep vascular plexus will be examined to look for the decrease of ischemia in peripapillary and macular areas.

  5. improvement of other manifestations of GCA [ Time Frame: weeks 4, 8, and 13 ]
    Proportion of patients with improvement of other manifestations of GCA with tocilizumab and prednisone at weeks 4, 8, and 13

  6. biological improvement [ Time Frame: weeks 4, 8, and 13 ]
    Proportion of patients with biological improvement (i.e. CRP and ESR) with tocilizumab and prednisone at weeks 4, 8, and 13

  7. recurrence of AION [ Time Frame: week 13 ]
    Influence of 1-month tocilizumab treatment on recurrence of AION, at W13.

  8. recurrence of GCA [ Time Frame: Week 13 ]
    Influence of 1-month tocilizumab treatment on recurrence of GCA, at Week 13.

  9. first recurrence of GCA [ Time Frame: weeks 1, 2, 3, 4, 8 and 13 ]
    Time to first recurrence of GCA

  10. Immunological biomarkers [ Time Frame: weeks 0,4 and 13 ]
    Immunological biomarkers of response to Tocilizumab assessed at W0, W4, and W13.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age of 50 years or older
  2. Social insurance
  3. Diagnosis of AION, characterized by sudden and painless loss of vision, of less than one week, accompanied by pallid swelling of the optic disc
  4. Sudden permanent visual loss due to AION, of less than one week
  5. Diagnosis of GCA based on the 1st (age ≥ 50 years) and the 3rd (Diagnosis of AION) criteria and at least one among the following :

    • One unequivocal symptom among: New onset localized headache, scalp or temporal artery tenderness, otherwise unexplained mouth or jaw pain under mastication, or unequivocal symptoms of polymyalgia rheumatic (shoulder and/or hip girdle pain associated with inflammatory stiffness).
    • Elevated erythrocyte sedimentation rate (≥ 50 at 1 hour) or C-reactive protein (≥ 10 mg/l), otherwise unexplained
    • Abnormal artery biopsy Biopsy specimen with artery showing vasculitis characterized by a predominance of mononuclear cell infiltration or granulomatous inflammation, usually with multinucleated giant cells.
    • Evidence of large or medium-size vessel vasculitis at ultrasound, magnetic resonance angiography, computed tomography angiography, or positron emission tomography-computed tomography.

Exclusion Criteria:

  • Other ocular involvements related to GCA (central retinal artery occlusion, posterior ischemic optic neuropathy, transient ocular manifestations, occipital stroke), if not associated with AION
  • Biological targeting therapy within 3 months preceding the study
  • Evidence of active infection
  • History of any malignant neoplasm except adequately treated basal or squamous cell carcinoma of the skin or solid tumors treated with curative therapy and disease-free for at least 5 years
  • History of recurrent infections, diverticulitis or intestinal ulceration and ASAT/ALAT > 5 * upper limit of normal, according to the Summary of Product Characteristics of tocilizumab
  • Contraindication to steroids and/or aspirin administrated in the treatment
  • Breastfeeding women and women with childbearing potential without highly effective contraception.
  • Pregnant or nursing (lactating) women confirmed by a positive βHCG laboratory test at the inclusion
  • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during study treatment and for 3 months after the last administration of tocilizumab.
  • Cytopenia, as defined by platelet count < 100 × 109/L (100,000/mm3), hemoglobin < 85 g/L (8.5 g/dL; 5.3 mmol/L), absolute neutrophil count < 2.0 × 109/L (2000/mm3), absolute lymphocyte count < 0.5 × 109/L (500/mm3)
  • Insufficient liver function (Child Pugh C )
  • Insufficient kidney function, as defined by a serum creatinine of more than 3 mg/dL or creatinine clearance of 20 ml/min or less
  • Patients with previously untreated tuberculosis, previously known TDM/radiographic evidence suggestive of active and/or sequellar tuberculosis
  • HIV infected, hepatitis C infected, or a positive hepatitis B surface antigen if known before study inclusion
  • Contraindication to and precaution in use of tocilizumab according to the summary product description
  • Inability to provide informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04239196


Contacts
Layout table for location contacts
Contact: Tania RILCY +33 140021126 trilcy@15-20.fr
Contact: Hayet SERHANE +33 140021144 hserhane@15-20.fr

Locations
Layout table for location information
France
CHU de Caen - Hôpital de la Côte de Nacre Active, not recruiting
Caen, France, 14033
Hôpital François Mitterrand Recruiting
Dijon, France, 21000
Contact: Maxime Samson    03 80 29 34 32    maxime.samson@chu-dijon.fr   
CHU de Limoges Active, not recruiting
Limoges, France, 87042
CH Montfermeil Active, not recruiting
Montfermeil, France, 93370
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts Recruiting
Paris, France, 75012
Contact: Emmanuel Heron, MD    0140021604    eheron@15-20.fr   
Saint-Antoine Hospital Recruiting
Paris, France, 75012
Contact: Arsene Mekinian, MD    0149282104 ext +33    arsene.mekinian@aphp.fr   
Pitié-Salpetrière Hospital Active, not recruiting
Paris, France, 75013
Cochin Hospital Recruiting
Paris, France, 75014
Contact: Benjamin terrier, MD, PHD    01 58 41 14 61    benjamin.terrier@aphp.fr   
Fondation Rothschild, Recruiting
Paris, France, 75019
Contact: Catherine Vignal    0148036881    cvignal@for.paris   
Groupe Hospitalier Diaconesses-Croix Saint Simon, Active, not recruiting
Paris, France, 75020
Sponsors and Collaborators
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Roche Chugai
Investigators
Layout table for investigator information
Principal Investigator: Emmanuel Heron, MD Centre Hospitalier National d'Ophtalmologie des Quinze-Vints
Layout table for additonal information
Responsible Party: Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
ClinicalTrials.gov Identifier: NCT04239196    
Other Study ID Numbers: P17-03
2019-001145-40 ( EudraCT Number )
First Posted: January 23, 2020    Key Record Dates
Last Update Posted: March 18, 2022
Last Verified: March 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Polymyalgia Rheumatica
Giant Cell Arteritis
Arteritis
Optic Neuropathy, Ischemic
Vasculitis
Vascular Diseases
Cardiovascular Diseases
Vasculitis, Central Nervous System
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Skin Diseases, Vascular
Skin Diseases
Autoimmune Diseases
Immune System Diseases
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Optic Nerve Diseases
Cranial Nerve Diseases
Eye Diseases